US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kailera Therapeutics

14.70

-0.1450-0.98%

Volume:106.29K

Turnover:1.57M

Market Cap:1.90B

PE:-6.52

High:14.98

Open:14.58

Low:14.51

Close:14.84

52wk High:28.23

52wk Low:14.51

Shares:129.54M

Float Shares:44.92M

Volume Ratio:0.64

T/O Rate:0.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2543

EPS(LYR):-7,819.9811

ROE:-36.90%

ROA:-22.73%

PB:1.70

PE(LYR):0.00

Loading ...

Overview Company News Filings

Analysts Offer Insights on NA Companies: Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (KLRA)

ADVISORY-Research alert on Kailera Therapeutics withdrawn

Kailera Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating; Price Target $57

THOMSON REUTERS

This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst

Kailera presents Phase 1 ribupatide injection data supporting global Phase 3 KaiNETIC program at ADA

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

Kailera Therapeutics initiated with an Outperform at Evercore ISI

Kailera Therapeutics Initiated at Outperform by Evercore ISI Group

Kailera Therapeutics Initiated at Overweight by JP Morgan

JPMorgan Initiates Kailera Therapeutics at Overweight With $30 Price Target

MT Newswires Live

Jefferies Initiates Kailera Therapeutics at Buy With $48 Price Target

MT Newswires Live

Evercore ISI Kailera Therapeutics Initiates at Outperform

MT Newswires Live

Kailera Therapeutics Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $36

THOMSON REUTERS

Kailera Therapeutics initiated with a Buy at TD Cowen

Analysts Offer Insights on NA Companies: Douglas AG (OtherDOUDF) and Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics initiated with an Outperform at William Blair

Biotech firm Odyssey targets $810 million valuation in US IPO

Kailera Therapeutics IPO Debut And Index Inclusion Spur Early Assessment

Simply Wall St.

Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy

Benzinga_recent_news

Major Investor Makes Bold Move Into Kailera Therapeutics

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/KLRA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KLRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics","latestPrice":14.695,"timestamp":1789052311412,"preClose":14.84,"halted":0,"volume":106286,"delay":0,"changeRate":-0.00977088948787059,"floatShares":44921899,"shares":129537300,"eps":-2.254252,"marketStatus":"Trading","change":-0.145,"latestTime":"09-10 10:58:37 EDT","open":14.58,"high":14.975,"low":14.51,"amount":1565214.295554,"amplitude":0.031334,"askPrice":14.74,"askSize":121,"bidPrice":14.66,"bidSize":50,"shortable":0,"etf":0,"ttmEps":-2.254252,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":2,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":14.84,"preHourTrading":{"tag":"盘前","latestPrice":14.56,"preClose":14.84,"latestTime":"09:29 EDT","volume":416,"amount":6075.959968,"timestamp":1789046999999,"change":-0.28,"changeRate":-0.018868,"amplitude":0.009434},"postHourTrading":{"tag":"盘后","latestPrice":14.43,"preClose":14.84,"latestTime":"19:51 EDT","volume":14865,"amount":219893.46,"timestamp":1788997880189,"change":-0.41,"changeRate":-0.027628,"amplitude":0.027628},"volumeRatio":0.638265},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","floatShares":44921899,"roa":"-22.73%","roe":"-36.90%","lyrEps":-7819.9811,"volumeRatio":0.638265,"shares":129537300,"dividePrice":0,"high":14.975,"amplitude":0.031334,"preClose":14.84,"low":14.51,"week52Low":14.51,"pbRate":"1.70","week52High":28.2271,"institutionHeld":0,"latestPrice":14.695,"committee":-0.415205,"eps":-2.254252,"divideRate":0,"volume":106286,"delay":0,"ttmEps":-2.254252,"open":14.58,"prevYearClose":16,"prevWeekClose":16.23,"prevMonthClose":15.4,"prevQuarterClose":22.03,"fiveDayClose":15.85,"twentyDayClose":18.59,"sixtyDayClose":19.67},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"KLRA","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1783483200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRA","date":"2026-09-09","current":-6.518792,"percent":0.939394,"low":-21.871461,"twenty":-19.474134,"median":-13.590258,"eighty":-10.452335,"high":-6.832762,"avg":-14.47641,"sd":4.702358,"marketCap":2130045596},"quantilePoints":[{"date":"2026-04-17","current":-12.669466,"twenty":-12.511098,"median":-12.273546,"eighty":-12.035993,"marketCap":1887180368},{"date":"2026-04-24","current":-20.824025,"twenty":-20.917019,"median":-20.433783,"eighty":-14.17085,"marketCap":3101842710},{"date":"2026-05-01","current":-21.741015,"twenty":-21.413894,"median":-20.305085,"eighty":-18.829635,"marketCap":3238432850},{"date":"2026-05-08","current":-19.540824,"twenty":-21.576784,"median":-20.824025,"eighty":-19.524523,"marketCap":2910703445},{"date":"2026-05-15","current":-18.697273,"twenty":-21.521865,"median":-20.058623,"eighty":-18.676401,"marketCap":2785052251},{"date":"2026-05-22","current":-18.332024,"twenty":-21.403595,"median":-19.540824,"eighty":-18.304195,"marketCap":2730646579},{"date":"2026-05-29","current":-19.949555,"twenty":-21.097481,"median":-19.520448,"eighty":-18.332024,"marketCap":2971585983},{"date":"2026-06-05","current":-18.253756,"twenty":-20.940268,"median":-19.530636,"eighty":-18.332024,"marketCap":2718988220},{"date":"2026-06-12","current":-16.992777,"twenty":-20.824025,"median":-19.392985,"eighty":-17.13192,"marketCap":2531159115},{"date":"2026-06-18","current":-16.636224,"twenty":-20.511831,"median":-18.758148,"eighty":-17.050173,"marketCap":2478048816},{"date":"2026-06-26","current":-12.75669,"twenty":-20.227867,"median":-18.684228,"eighty":-17.050173,"marketCap":2676825461},{"date":"2026-07-02","current":-12.855483,"twenty":-20.165517,"median":-18.622605,"eighty":-16.764931,"marketCap":2697555958},{"date":"2026-07-10","current":-12.9728,"twenty":-20.033041,"median":-18.410291,"eighty":-15.433812,"marketCap":2722173424},{"date":"2026-07-17","current":-11.311837,"twenty":-19.949555,"median":-18.314631,"eighty":-13.521103,"marketCap":2373641938},{"date":"2026-07-24","current":-10.743775,"twenty":-19.944337,"median":-17.453687,"eighty":-12.859187,"marketCap":2254441579},{"date":"2026-07-31","current":-10.527665,"twenty":-19.923466,"median":-17.13192,"eighty":-12.704356,"marketCap":2209093616},{"date":"2026-08-07","current":-11.651439,"twenty":-19.849563,"median":-17.071044,"eighty":-11.79378,"marketCap":2444903022},{"date":"2026-08-14","current":-7.973035,"twenty":-19.724778,"median":-16.992777,"eighty":-11.573639,"marketCap":2329696857},{"date":"2026-08-21","current":-7.746755,"twenty":-19.603438,"median":-16.640572,"eighty":-11.334065,"marketCap":2263578582},{"date":"2026-08-28","current":-8.221499,"twenty":-19.532674,"median":-16.131833,"eighty":-11.014222,"marketCap":2402297316},{"date":"2026-09-04","current":-6.983615,"twenty":-19.497291,"median":-13.667441,"eighty":-10.594351,"marketCap":2040591460},{"date":"2026-09-09","current":-7.289759,"twenty":-19.474134,"median":-13.590258,"eighty":-10.452335,"marketCap":2130045596}],"updateTime":1789052317049},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636418018","title":"Analysts Offer Insights on NA Companies: Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636418018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636418018?lang=en_us&edition=fundamental","pubTime":"2026-05-18 00:41","pubTimestamp":1779036113,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (K...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-arxis-inc-class-a-arxs-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-arxis-inc-class-a-arxs-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4141","KLRA","BK4139","ARXS","BK4187","NA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635762235","title":"ADVISORY-Research alert on Kailera Therapeutics withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2635762235","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635762235?lang=en_us&edition=fundamental","pubTime":"2026-05-14 13:25","pubTimestamp":1778736345,"startTime":"0","endTime":"0","summary":"ADVISORY-Research alert on Kailera Therapeutics withdrawnMay 14 (Reuters) - An alert on TD Cowen starting coverage on Kailera Therapeutics Inc KLRA.O is dated and has been withdrawn. There will be no ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nFWN41R08Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635625727","title":"Kailera Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating; Price Target $57","url":"https://stock-news.laohu8.com/highlight/detail?id=2635625727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635625727?lang=en_us&edition=fundamental","pubTime":"2026-05-14 13:08","pubTimestamp":1778735305,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nFWN41R08Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635751444","title":"This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2635751444","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635751444?lang=en_us&edition=fundamental","pubTime":"2026-05-14 02:43","pubTimestamp":1778697780,"startTime":"0","endTime":"0","summary":"William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/05/13/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/05/13/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/05/52539772/this-weight-loss-drug-challenger-could-follow-eli-lillys-playbook-analyst","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/05/52539772/this-weight-loss-drug-challenger-could-follow-eli-lillys-playbook-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU0096364046.USD","LU0097036916.USD","LU0964807845.USD","LU1366192091.USD","LU1989771016.USD","SGXZ57979304.SGD","LU1720051017.SGD","LU0471298777.SGD","SG9999017495.SGD","LU2168564149.EUR","LU2063271972.USD","LU1323610961.USD","LU2456880835.USD","IE00BKPKM429.USD","LU1064131342.USD","LU1629891620.HKD","LU2112291526.USD","LU0823416689.USD","LU1551013342.USD","LU0889565916.HKD","LU1291159041.SGD","LU2213496289.HKD","SG9999001176.USD","IE00B2B36J28.USD","IE00BK4W5M84.HKD","LLY","LU2324357040.USD","LU0640476718.USD","IE00B775H168.HKD","LU2089283258.USD","IE00B1XK9C88.USD","SG9999015986.USD","LU0385154629.USD","LU2106854487.HKD","LU1712237335.SGD","IE00BWXC8680.SGD","LU2746668461.USD","LU2168564495.EUR","LU2168563687.JPY","LU2471134523.USD","IE00BJJMRY28.SGD","SG9999014880.SGD","SG9999014914.USD","LU1267930730.SGD","LU0198837287.USD","IE00B7KXQ091.USD","LU2471134952.CNY","SGXZ81514606.USD","LU0058720904.USD","LU0787776722.HKD","IE0005OL40V9.USD","LU1145028129.USD","LU1988902786.USD","LU2023250504.SGD","LU2237443978.SGD","BK4585","LU0106261372.USD","LU0672654240.SGD","BK4534","LU2089284900.SGD","LU0689472784.USD","LU2028103732.USD","LU1868836591.USD","LU1983299246.USD","SG9999018865.SGD","LU2361045086.USD","BK4588","LU1093756168.USD","LU2108987350.USD","ELIS","LU2602419157.SGD","IE00BN29S564.USD","LU0234572021.USD","LU2491050071.SGD","IE00BJLML261.HKD","LU0786609619.USD","LU2271345857.HKD","LU2756315664.SGD","BK4599","LU2417539215.USD","LU2552382132.HKD","LU2361044949.HKD","LU1548497426.USD","LU2462157665.USD","LU2756315318.SGD","SG9999018857.SGD","LU2111349929.HKD","BK4516","LU2023250330.USD","IE00BFSS7M15.SGD","LU0114720955.EUR","LU2896262040.SGD","IE0009355771.USD","LU0109391861.USD","LU2746668974.SGD","IE00BFSS8Q28.SGD","IE0002141913.USD","KLRA","LU0203202063.USD","SGXZ51526630.SGD","LU0122379950.USD","LU0820562030.AUD","LU2264538146.SGD","SGXZ31699556.SGD","BK4581","LU0471298694.HKD","LU1057294990.SGD","LU0316494557.USD","LLII","LU0006306889.USD","LU0466842654.USD","LU0061475181.USD","LU1035775433.USD","LU0289739699.SGD","LLYZ","LU0320765992.SGD","LU1868836914.USD","SGXZ99366536.SGD","IE00BJJMRX11.SGD","LU0417517546.SGD","LU2237443382.USD","LU0456855351.SGD","LU2236285917.USD","LU2468319806.SGD","LU2237443895.HKD","LU1720051108.HKD","SG9999015945.SGD","IE00BJT1NW94.SGD","LU2237443465.HKD","LU0210536198.USD","LU0683600562.USD","LU2552382215.SGD","LU0353189680.USD","SG9999014898.SGD","LU0354030511.USD","LU2211815571.USD","ELIL","LU2471134879.HKD","IE00B4JS1V06.HKD","LU1061106388.HKD","LU2491049909.HKD","LU0882574055.USD","IE00BFTCPJ56.SGD","LU0238689110.USD","SG9999001176.SGD","LU2471134796.USD","LU2168564065.EUR","SG9999013999.USD","LU2168564222.USD","LLYX","LU1551013425.SGD","SG9999014906.USD","LU0820561818.USD","LU2552382058.USD","IE0001KFT4U8.USD","LU0432979614.USD","LU1868837300.USD","LU1069344957.HKD","LU0256863811.USD","SG9999015978.USD","LU0708995401.HKD","LU2750360641.GBP","LU0823434740.USD","LU0943347566.SGD","LU0133085943.USD","LU0094547139.USD","IE0004445239.USD","LU1023059063.AUD","LU1093756325.SGD","SG9999015952.SGD","LU0323591593.USD","LU2360106947.USD","LU1232071149.USD","IE00BKDWB100.SGD","LU0820561909.HKD","LU1868836757.USD","LU0320765059.SGD","BK4007","IE00BK4W5L77.USD","IE0004445015.USD","LU1868837136.USD","LU2237443622.USD","BK4533","LU2087625088.SGD","LU0823434583.USD","LU0203201768.USD","LU2265009873.SGD","IE00BJJMRZ35.SGD","LU1804176565.USD","LU1814569148.SGD","LU1280957306.USD","LU2750360997.AUD","IE00B1BXHZ80.USD","LU0225283273.USD","LU1127390331.HKD","LU1623119135.USD","LU0354030438.USD","GB00BDT5M118.USD","LU0256863902.USD","LU1917777945.USD","LU2461242641.AUD","LU0266013472.USD","LU2237438978.USD","LU2491050154.USD","LU0158827948.USD","LU1974910355.USD","LU2357305700.SGD","LU0158827781.USD","LU2361044865.SGD","LU0079474960.USD","LU0882574139.USD","LU0353189763.USD","LU2089984988.USD","IE00B4R5TH58.HKD","LU0109394709.USD","LU2023251221.USD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635789072","title":"Kailera presents Phase 1 ribupatide injection data supporting global Phase 3 KaiNETIC program at ADA","url":"https://stock-news.laohu8.com/highlight/detail?id=2635789072","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635789072?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:31","pubTimestamp":1778671895,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics announced 2 clinical data poster presentations on ribupatide, its dual GLP-1/GIP agonist program for obesity and overweight, scheduled for June 5-8, 2026 at American Diabetes Association 86th Scientific Sessions in New Orleans.Results have not yet been presented; Kailera plans to show Phase 1 bridging study data for injectable ribupatide on June 8.Study readout supported initiation of Kailera ongoing global Phase 3 KaiNETIC clinical program, positioning injectable ribupatide as lead near-term value driver in its obesity pipeline.Partner Hengrui Pharma will also present Phase 2 results for oral ribupatide on June 7, expanding optionality across oral and injectable formats without disclosing outcomes in this announcement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL3vdWDt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU2210149790.SGD","BK4588","KLRA","LU2095319765.USD","BK4112","SG9999014021.USD","SG9999014013.SGD","LU2210150020.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014005.SGD","NDAQ","BK4139","BK4585","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635878901","title":"Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2635878901","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635878901?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:30","pubTimestamp":1778671800,"startTime":"0","endTime":"0","summary":"Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and ove","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293890/0/en/Hengrui-Pharma-and-Kailera-Therapeutics-Announce-Clinical-Data-Presentations-at-the-American-Diabetes-Association-86th-Scientific-Sessions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","KLRA","BK4107","BK4139","AFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635724525","title":"Kailera Therapeutics initiated with an Outperform at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2635724525","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635724525?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:50","pubTimestamp":1778601012,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Umer Raffat initiated coverage of Kailera Therapeutics (KLRA) with an Outperform rating and no price target Kailera is “making...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-an-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-an-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634245888","title":"Kailera Therapeutics Initiated at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2634245888","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634245888?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:36","pubTimestamp":1778600160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KLRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 11:36 ET (15:36 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634248399","title":"Kailera Therapeutics Initiated at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2634248399","media":"Dow Jones","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634248399?lang=en_us&edition=fundamental","pubTime":"2026-05-12 22:39","pubTimestamp":1778596740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KLRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 10:39 ET (14:39 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634213491","title":"JPMorgan Initiates Kailera Therapeutics at Overweight With $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2634213491","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634213491?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:16","pubTimestamp":1778584605,"startTime":"0","endTime":"0","summary":"JPMorgan Initiates Kailera Therapeutics at Overweight With $30 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JPM","PGF","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634213464","title":"Jefferies Initiates Kailera Therapeutics at Buy With $48 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2634213464","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634213464?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:14","pubTimestamp":1778584463,"startTime":"0","endTime":"0","summary":"Jefferies Initiates Kailera Therapeutics at Buy With $48 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634139662","title":"Evercore ISI Kailera Therapeutics Initiates at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2634139662","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634139662?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:13","pubTimestamp":1778584422,"startTime":"0","endTime":"0","summary":"Evercore ISI Kailera Therapeutics Initiates at Outperform","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634297885","title":"Kailera Therapeutics Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $36","url":"https://stock-news.laohu8.com/highlight/detail?id=2634297885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634297885?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:04","pubTimestamp":1778580293,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P108:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634292860","title":"Kailera Therapeutics initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2634292860","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634292860?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:37","pubTimestamp":1778578626,"startTime":"0","endTime":"0","summary":"TD Cowen initiated coverage of Kailera Therapeutics (KLRA) with a Buy rating and $57 price target The company’s lead asset ribupatide is “different...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA","BK4207","BK4139","TD","BK4127","COWN","BK4585","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634291061","title":"Analysts Offer Insights on NA Companies: Douglas AG (OtherDOUDF) and Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634291061","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634291061?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:21","pubTimestamp":1778577672,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Douglas AG (DOUDF) and Kailera Therapeutics, Inc. (KLRA) wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-douglas-ag-otherdoudf-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-douglas-ag-otherdoudf-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AG","BK4210","BK4139","BK4141","BK4200","KLRA","DOUDF","NA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634294839","title":"Kailera Therapeutics initiated with an Outperform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2634294839","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634294839?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:15","pubTimestamp":1778577310,"startTime":"0","endTime":"0","summary":"William Blair analyst Andy Hsieh initiated coverage of Kailera Therapeutics (KLRA) with an Outperform rating. Kailera is advancing a pipeline of GL...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-an-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-initiated-with-an-outperform-at-william-blair-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632932017","title":"Biotech firm Odyssey targets $810 million valuation in US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2632932017","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632932017?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:48","pubTimestamp":1777891715,"startTime":"0","endTime":"0","summary":"UPDATE 2-Biotech firm Odyssey targets $810 million valuation in US IPOAdds details throughout. May 4  - Biopharmaceutical company Odyssey Therapeutics said on Monday it is targeting a valuation of up to $809.9 million in its initial public offering in the United States, as investors warm up to drug developers. The Boston-based company is seeking to raise up to $238.3 million by offering 13.2 million shares priced between $16 and $18 apiece. The U.S. IPO market has made a strong comeback in recent weeks, setting the stage for a pickup in listings in coming months.Last month, weight-loss drug developer Kailera Therapeutics KLRA.O, Alamar Biosciences ALMR.O and nuclear reactor maker X-Energy XE.O made stellar market debuts.April marked the biggest month for new filings in more than four years, according to Renaissance Capital, a provider of IPO-focused research and ETFs. This despite a volatile first quarter amid a sell-off in tech stocks, private credit strains and the Middle East confli","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL4N41H0NW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0724617625.USD","ALMR","NVD2.UK","NVDX","SGXZ23171101.USD","NVDA","LU1803068979.SGD","NVDL","LU0345768740.USD","LU2420271590.USD","LU0310799852.SGD","NVDQ","NVDG","IE00B3SWFQ91.USD","NVDO","NVD","BK4532","LU0965509283.SGD","NVD3.UK","DIPS","LU1934455277.USD","LU2236285917.USD","LU1989772923.USD","LU2756315664.SGD","NVDU","SGXZ81514606.USD","LU0072462426.USD","NVDS","ANV","BK4533","LU0061474705.USD","NVDW","LU0265550359.USD","SNVD.UK","2NVD.UK","XE","IE000YTNTUN2.SGD","NVDB","KLRA","LU0345768153.USD","LU1267930490.SGD","NVDD","NVDY","NVII","3NVD.UK","LU0158827948.USD","LU1153585028.USD","NVIW.SI","LU2552382132.HKD","NVDS.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629852200","title":"Kailera Therapeutics IPO Debut And Index Inclusion Spur Early Assessment","url":"https://stock-news.laohu8.com/highlight/detail?id=2629852200","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629852200?lang=en_us&edition=fundamental","pubTime":"2026-04-24 02:12","pubTimestamp":1776967958,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics completed its IPO and began trading on the Nasdaq Global Select Market under the ticker NasdaqGS:KLRA.\nThe company has been added to the NASDAQ Composite Index, broadening its exposure to index-tracking investors.\nShares most recently closed at $24.30, with a year-to-date return reflecting a 6.5% decline.\n\n\nKailera Therapeutics, now trading as NasdaqGS:KLRA, has moved from private funding into the public markets with its Nasdaq Global Select Market listing. With a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-klra/kailera-therapeutics/news/kailera-therapeutics-ipo-debut-and-index-inclusion-spur-earl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-klra/kailera-therapeutics/news/kailera-therapeutics-ipo-debut-and-index-inclusion-spur-earl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NQmain","QID","IPOS","QDTE",".IXIC","NVIW.SI","KLRA","GPIQ","QYLG","ONEQ","QQQA","QQQE","QQQ","QLD","QQQM","NDX","FTEC","SPCX","SQQQ","MNQmain","PSQ","QQQY","IYW","JEPQ","TQQQ","QQQJ","TQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629599348","title":"Kailera Therapeutics' Strong IPO Validates \"NewCo\" Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2629599348","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629599348?lang=en_us&edition=fundamental","pubTime":"2026-04-24 00:08","pubTimestamp":1776960480,"startTime":"0","endTime":"0","summary":"A company set up to develop Hengrui Pharma's weight-loss drugs has made a strong debut on the U.S. equity market, building confidence in the \"NewCo\" business model. When Chinese drugmakers began spinning off promising pipelines into standalone companies, they faced market concern and skepticism. The strategy was considered an unproven and potentially risky way to monetize their clinical assets.But the attitude towards these so-called NewCos – corporate vehicles housing specific drugs under development – has brightened this year after one of the Chinese spin-offs was bought out by a multinational, delivering a big payoff for the original developer.The newly listed firm was set up as a corporate wrapper for Hengrui Pharma's GLP-1 assets, with shareholders including Bain Capital Life Sciences, Atlas Venture, RTW Investments and Lyra Capital, along with other specialized investment institutions. The Kailera share price surged about 63% on its first U.S. trading day, offering a windfall opp","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/23/-23-4-2026-101430-thebambooworks-com.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/23/-23-4-2026-101430-thebambooworks-com.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/26/04/52006951/kailera-therapeutics-strong-ipo-validates-newco-strategy","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/Opinion/26/04/52006951/kailera-therapeutics-strong-ipo-validates-newco-strategy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IPOS","KLRA","SPCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629070227","title":"Major Investor Makes Bold Move Into Kailera Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2629070227","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629070227?lang=en_us&edition=fundamental","pubTime":"2026-04-23 10:01","pubTimestamp":1776909701,"startTime":"0","endTime":"0","summary":"New insider activity at Kailera Therapeutics, Inc. ( ($KLRA) ) has taken place on April 22, 2026. Significant shareholder RTW INVESTMENTS, LP has i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-makes-bold-move-into-kailera-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-makes-bold-move-into-kailera-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":80,"code":"91000000","status":"200"}]}}